Tyrosine Kinase Inhibitor

The use of genomic testing to identify actionable mutations and match patients to targeted therapies has had a dramatic impact on cancer treatment.

Choosing the best treatment for a patient with renal cell carcinoma involves a thorough assessment of the potential advantages and drawbacks of each targeted and immune therapy option based on the patient’s risk level and adjustment based on response to frontline treatment.

More than half of a cohort of children and young adults with multiple endocrine neoplasia type 2B had restrictive and obstructive lung abnormalities and 94% showed some degree of diminished lung function, NIH study data showed.

Masitinib significantly reduced asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids compared with placebo treatment, according to new data.

Healio spoke with Edward S. Kim, MD, chair of the department of solid tumor oncology at Levine Cancer Institute at Atrium Health in Charlotte, North Carolina, about stress management and how stress hormones can promote epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer.

Discontinuation of first-line dasatinib after 3 years of treatment appeared safe among a cohort of patients with chronic myeloid leukemia who had achieved a sustained deep molecular response, according to results of the single-arm, multicenter, phase 2 DADI trial published in The Lancet Haematology.

The FDA granted priority review to ripretinib for treatment of advanced gastrointestinal stromal tumors, according to a press release from the agent’s manufacturer.

Dasatinib appeared more effective than imatinib mesylate for treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to results of a randomized phase 3 clinical trial published in JAMA Oncology.

ORLANDO — The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition.

The introduction of targeted therapies in the management of metastatic renal cell carcinoma has markedly increased the treatment options available for these patients. These agents are now used in the first-line and second-line treatment settings, and beyond, to improve patient outcomes. Although many of these agents were approved on the basis of an improvement in progression-free survival, a recent analysis of a real-world patient population found that the use of targeted therapy has led to improved survival as well.